Welcome to our dedicated page for DEXCOM SEC filings (Ticker: DXCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
DexCom, Inc. filings document formal disclosures for its continuous glucose monitoring and glucose biosensing business. Recent 8-K reports cover quarterly and annual financial results, preliminary financial outlook, revenue by geography, operating income, non-GAAP measures, and exhibits containing earnings releases.
Dexcom proxy and governance filings address annual meeting matters, board composition, committee assignments, director independence, executive compensation, pay-versus-performance disclosures, equity awards, indemnity arrangements, and leadership-related compensation terms. The filing record also reflects material-event reporting for board appointments and other governance changes.
DEXCOM INC director Nicholas Augustinos reported a bona fide gift of 1,075 shares of Dexcom common stock on 2026-08-12. The donated shares were held indirectly through the Kirschner/Augustinos Revocable Trust and were contributed to a charitable donor advised fund, leaving 37,382 shares held by the trust. Separately, Augustinos holds 5,575 unvested restricted stock units granted on May 28, 2026, which will vest on the earlier of the one-year anniversary of that grant or DexCom, Inc.'s 2027 Annual Meeting of Stockholders.
DexCom Inc. director Bridgette P. Heller reported an open-market sale of 1,012 shares of Common Stock on August 12, 2026 at $88.29 per share. The sale was executed under a Rule 10b5-1 trading plan adopted on August 14, 2025. After this transaction, she directly holds 29,570 shares, including 5,575 unvested restricted stock units that were granted on May 28, 2026 and will vest on the earlier of the one-year anniversary of the grant date or DexCom’s 2027 Annual Meeting of Stockholders.
DexCom, Inc. insider Bridgette P. Heller filed a notice of proposed sale of 1,012 shares of common stock of DXCM, to be sold through Fidelity Brokerage Services LLC on or after August 12, 2026 on NASDAQ. The shares were acquired via restricted stock vesting from the issuer as compensation on September 29, 2021. Heller also reported having sold 1,012 common shares during the past three months on May 12, 2026 for $60,730.12.
A family trust associated with DexCom Inc. director Mark G. Foletta sold 4,000 shares of common stock in two indirect open-market transactions: 2,000 shares at $80.00 on July 31, 2026 and 2,000 shares at $85.32 on August 3, 2026, pursuant to a pre‑arranged 10b5‑1 Plan adopted by the Foletta Family Trust on March 13, 2026.
Foletta also directly holds 6,331 unvested restricted stock units granted on May 28, 2026, scheduled to vest on the earlier of the one‑year grant anniversary or DexCom’s 2027 annual meeting of stockholders.
DexCom, Inc. (DXCM) has a planned sale by The Foletta Family Trust under a Form 144 notice. The trust intends to sell 2,000 shares of common stock through UBS Financial Services on NASDAQ, with an indicated aggregate value of $170,640.00. The shares derive from 2,000 vested RSUs granted by the issuer on 05/31/2019.
The filing also lists recent sales by the trust: 4,000 shares of common stock sold on 06/15/2026 for $296,539.60, and 2,000 shares sold on 07/31/2026 for $160,000.00. These transactions provide context for the trust’s ongoing disposition of DXCM shares.
DexCom, Inc. (DXCM) has a planned sale of 2,000 shares of common stock through UBS Financial Services, Inc., with an aggregate market value of $160,000.00, listed on NASDAQ and expected on July 31, 2026. The shares originate from vested RSUs granted in 2019 and 2026. A related holder, The Foletta Family Trust dtd 1/30/2015, previously sold 4,000 common shares on June 15, 2026 for $296,539.60.
DexCom generated strong results for the quarter ended June 30, 2026, with revenue of $1,308.4 million, up 13% year over year, and gross profit of $830.0 million, raising gross margin to 63.4% from 59.5%. Operating income rose to $318.3 million (up 50%), and net income to $249.1 million (up 39%), or $0.64 diluted EPS, driven mainly by higher disposable sensor volumes, continued expansion of the worldwide customer base, and favorable revenue per customer, partly offset by channel/product mix, rebate eligibility, and higher inventory reserves tied to the planned discontinuation of G6 manufacturing.
For the first six months of 2026, revenue reached $2,500.3 million (up 14%) and net income $448.6 million (up 57%), as G7 15 Day benefits, improved manufacturing efficiencies, higher production volumes and a more favorable manufacturing mix lifted margins despite larger excess and obsolete inventory charges of $84.2 million. Operating cash flow was $794.8 million, and DexCom ended the period with $1.95 billion in cash, cash equivalents and short-term marketable securities. Capital allocation included repurchasing 8.6 million shares for $600.0 million under the 2026 Share Repurchase Program, while maintaining $1.25 billion of 0.375% senior convertible notes due 2028 and an undrawn $200.0 million revolving credit facility (aside from $8.7 million in letters of credit).
Dexcom reported financial results for the quarter ended June 30, 2026. Revenue grew 13% year-over-year to $1.308 billion, with U.S. revenue up 11% and international revenue up 19%. GAAP gross margin was 63.4% and non-GAAP gross margin 64.1%. GAAP operating income was $318.3 million, a 24.3% margin, while non-GAAP operating income was $328.3 million, or 25.1% of revenue. GAAP net income was $249.1 million, or $0.64 per diluted share, and non-GAAP net income was $269.1 million, or $0.70 per diluted share. Adjusted EBITDA was $421.3 million.
Strategic updates included a 2026 Investor Day, positive CONNECT trial results in type 2 diabetes patients not using insulin, and the launch of a redesigned Stelo app with AI-driven insights. Dexcom raised the midpoint of 2026 revenue guidance to $5.18–$5.25 billion and increased targets for Non-GAAP Gross Profit Margin to about 64%, Non-GAAP Operating Margin to 23.5–24%, and Adjusted EBITDA Margin to 31.5–32%. As of June 30, 2026, Dexcom held $1.95 billion in cash, cash equivalents and marketable securities, with its revolving credit facility undrawn.
Dexcom Inc Executive Chair Kevin R. Sayer sold 26,756 shares of common stock on July 20, 2026 at a weighted average price of $76.3193 per share, in multiple trades between $75.80 and $76.62. The sale was made under a Rule 10b5-1 trading plan adopted on February 18, 2026 for orderly dispositions of his holdings. Following this sale, he directly holds 328,970 shares, including 106,972 unvested restricted stock units that were granted in 2024–2026 and will vest through 2028.
Dexcom, Inc. (DXCM) has a planned sale of common stock reported by affiliate Kevin R. Sayer. The notice covers up to 26,756 common shares to be sold through Morgan Stanley Smith Barney LLC Executive Financial Services, with an estimated aggregate market value of $2,041,999.19 as of the filing.
The shares derive from performance and restricted stock awarded on March 8, 2021. Dexcom reports 385,872,977 common shares outstanding, a baseline figure, not the amount being sold. In the past three months, Sayer sold 26,756 shares on July 6, 2026 for $1,926,432.00 and 26,759 shares on May 21, 2026 for $1,926,648.00.